{"hands_on_practices": [{"introduction": "Understanding the public health impact of a pharmacogenomic trait begins with population genetics. This practice uses the foundational Hardy–Weinberg principle to estimate the prevalence of different TPMT metabolizer phenotypes from a known allele frequency. By mastering this calculation, you can connect the frequency of a single nonfunctional allele in a population to the expected number of patients who are poor, intermediate, and normal metabolizers, a crucial first step in assessing the scope of a pharmacogenomic issue [@problem_id:4572485].", "problem": "In a clinical pharmacology context, consider Thiopurine Methyltransferase (TPMT), an enzyme whose activity influences thiopurine drug metabolism. Multiple nonfunctional alleles at the TPMT locus (for example, TPMT*2, TPMT*3A, TPMT*3C) contribute to reduced enzymatic activity. Assume a large, panmictic population with random mating, no migration, no selection on TPMT genotypes over the timescale of interest, and negligible recurrent mutation at this locus. Treat all nonfunctional TPMT alleles as functionally equivalent and completely recessive to the functional allele, and assume complete penetrance such that genotype-to-phenotype mapping is deterministic: individuals with two functional alleles are “normal metabolizers,” those with one functional allele and one nonfunctional allele are “intermediate metabolizers,” and those with two nonfunctional alleles are “poor metabolizers.” The combined population frequency of all nonfunctional TPMT alleles is given as $q = 0.05$, where the functional allele frequency is $1 - q$.\n\nUsing the Hardy–Weinberg equilibrium framework, derive from first principles and compute the expected frequencies (as fractions of the population) of normal, intermediate, and poor metabolizers for this population. Express each frequency as a decimal, and round each to four significant figures. Provide the final three values in the order: normal, intermediate, poor.", "solution": "This problem requires the application of the Hardy–Weinberg principle to determine the expected frequencies of different metabolizer phenotypes in a population. The problem statement provides all the necessary assumptions for this principle to be valid: a large, randomly mating (panmictic) population with no selection, migration, or mutation affecting the allele frequencies at the Thiopurine Methyltransferase (TPMT) locus.\n\nLet us define the alleles involved. We can represent the functional, or wild-type, allele as $W$ and the aggregated class of all nonfunctional alleles as $N$. The problem states that the nonfunctional alleles are recessively expressed with respect to the phenotype of interest, which is enzyme activity.\n\nThe frequencies of these alleles in the population's gene pool are denoted by $p$ and $q$, where:\n$p = \\text{frequency of the functional allele } (W)$\n$q = \\text{frequency of the nonfunctional alleles } (N)$\n\nThe problem gives the combined frequency of all nonfunctional alleles as $q = 0.05$.\nSince there are only two categories of alleles (functional and nonfunctional), their frequencies must sum to $1$.\n$$p + q = 1$$\nWe can, therefore, calculate the frequency of the functional allele, $p$:\n$$p = 1 - q = 1 - 0.05 = 0.95$$\n\nThe problem defines a deterministic relationship between genotype and phenotype:\n1.  **Normal metabolizers**: Individuals with two functional alleles. Their genotype is $WW$.\n2.  **Intermediate metabolizers**: Individuals with one functional and one nonfunctional allele. Their genotype is $WN$.\n3.  **Poor metabolizers**: Individuals with two nonfunctional alleles. Their genotype is $NN$.\n\nUnder Hardy–Weinberg equilibrium, the expected frequencies of these genotypes are given by the terms of the binomial expansion of $(p+q)^2$:\n$$(p+q)^2 = p^2 + 2pq + q^2 = 1$$\nWhere:\n-   The frequency of the $WW$ genotype is $p^2$.\n-   The frequency of the $WN$ genotype is $2pq$.\n-   The frequency of the $NN$ genotype is $q^2$.\n\nWe can now substitute the calculated allele frequencies, $p = 0.95$ and $q = 0.05$, into these equations to find the expected frequency of each phenotype.\n\n1.  **Frequency of Normal Metabolizers (genotype $WW$)**:\n    $$f(\\text{Normal}) = p^2 = (0.95)^2 = 0.9025$$\n\n2.  **Frequency of Intermediate Metabolizers (genotype $WN$)**:\n    $$f(\\text{Intermediate}) = 2pq = 2 \\times (0.95) \\times (0.05) = 2 \\times 0.0475 = 0.095$$\n\n3.  **Frequency of Poor Metabolizers (genotype $NN$)**:\n    $$f(\\text{Poor}) = q^2 = (0.05)^2 = 0.0025$$\n\nAs a verification, the sum of these frequencies should be $1$:\n$$0.9025 + 0.095 + 0.0025 = 1.0000$$\n\nThe problem requires that each frequency be expressed as a decimal rounded to four significant figures.\n-   The frequency of normal metabolizers, $0.9025$, already has four significant figures.\n-   The frequency of intermediate metabolizers is $0.095$. To express this to four significant figures, we add trailing zeros: $0.09500$.\n-   The frequency of poor metabolizers is $0.0025$. To express this to four significant figures, we add trailing zeros: $0.002500$.\n\nThe final answer should provide these three values in the order: normal, intermediate, poor.\n-   Frequency of normal metabolizers: $0.9025$\n-   Frequency of intermediate metabolizers: $0.09500$\n-   Frequency of poor metabolizers: $0.002500$", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.9025 & 0.09500 & 0.002500\n\\end{pmatrix}\n}\n$$", "id": "4572485"}, {"introduction": "Moving from the population to the individual, we must understand the biochemical consequences of genetic variation. This exercise applies the Michaelis–Menten model to explore how a genetically-driven reduction in TPMT enzyme concentration affects its metabolic activity. This practice provides a quantitative link between the 'genotype' (enzyme level) and the 'phenotype' (catalytic rate), a core concept in pharmacogenomics that explains how genetic differences manifest as functional changes in drug metabolism [@problem_id:4572500].", "problem": "Thiopurine methyltransferase (TPMT) is a cytosolic enzyme that catalyzes the S-methylation of thiopurine substrates such as $6$-mercaptopurine in a manner well modeled by steady-state Michaelis–Menten kinetics. In pharmacogenomics, certain thiopurine methyltransferase (TPMT) genetic variants predominantly decrease total functional enzyme concentration without altering substrate affinity. Consider a clinically realistic scenario in which a patient carries a TPMT genotype that reduces the total active enzyme concentration by $50\\%$ relative to a reference genotype, while the Michaelis constant $K_m$ remains unchanged. Let the baseline maximal velocity be denoted by $V_{\\max,0}$ and the substrate concentration by $[S]$. Assume the catalytic constant $k_{\\text{cat}}$ is unchanged and that the Michaelis–Menten framework applies over the clinically relevant range of $[S]$.\n\nStarting from fundamental definitions that connect catalytic turnover, total enzyme concentration, and steady-state reaction velocity under Michaelis–Menten kinetics, derive how a $50\\%$ reduction in total enzyme concentration affects the maximal velocity and the reaction velocity across all $[S]$. Report, as your final answer, the closed-form expression for the fold-change in reaction velocity across the entire range of $[S]$, expressed as a single exact, dimensionless constant. Do not provide any intermediate formulas or numeric approximations in the final answer. No rounding is required.", "solution": "The problem statement is evaluated as valid based on the required criteria. It is scientifically grounded in established principles of enzyme kinetics, well-posed with sufficient and consistent information, and objectively stated. The scenario described is a standard model in pharmacogenomics and presents a formalizable problem.\n\nThe analysis begins with the fundamental Michaelis-Menten equation, which describes the reaction velocity, $v$, as a function of substrate concentration, $[S]$:\n$$v = \\frac{V_{\\max} [S]}{K_m + [S]}$$\nHere, $V_{\\max}$ is the maximal reaction velocity and $K_m$ is the Michaelis constant.\n\nThe maximal velocity, $V_{\\max}$, is not a fundamental constant but is directly proportional to the total concentration of active enzyme, $[E]_{\\text{total}}$, and the catalytic constant (or turnover number), $k_{\\text{cat}}$. The relationship is given by:\n$$V_{\\max} = k_{\\text{cat}} [E]_{\\text{total}}$$\nThe catalytic constant, $k_{\\text{cat}}$, represents the number of substrate molecules converted to product per enzyme molecule per unit time when the enzyme is fully saturated with substrate.\n\nSubstituting this definition of $V_{\\max}$ into the Michaelis-Menten equation provides a more fundamental expression for the reaction velocity:\n$$v = \\frac{k_{\\text{cat}} [E]_{\\text{total}} [S]}{K_m + [S]}$$\n\nWe are asked to compare two scenarios: a reference state and a state corresponding to a patient with a specific TPMT genotype.\n\nLet us denote the reference state with a subscript $0$. The reaction velocity in the reference state, $v_0$, is given by:\n$$v_0 = \\frac{k_{\\text{cat}} [E]_{\\text{total},0} [S]}{K_m + [S]}$$\nwhere $[E]_{\\text{total},0}$ is the total active enzyme concentration in a subject with the reference genotype. We can also write this using the reference maximal velocity, $V_{\\max,0} = k_{\\text{cat}} [E]_{\\text{total},0}$:\n$$v_0 = \\frac{V_{\\max,0} [S]}{K_m + [S]}$$\n\nNow, consider the patient with the variant genotype. Let the new state be denoted with the subscript 'new'. The problem states that this genotype reduces the total active enzyme concentration by $50\\%$. Therefore, the new total enzyme concentration, $[E]_{\\text{total, new}}$, is:\n$$[E]_{\\text{total, new}} = (1 - 0.5) [E]_{\\text{total},0} = 0.5 [E]_{\\text{total},0}$$\n\nThe problem also states that the catalytic constant, $k_{\\text{cat}}$, and the Michaelis constant, $K_m$, remain unchanged by this genetic variant. The new maximal velocity, $V_{\\max, \\text{new}}$, can be expressed as:\n$$V_{\\max, \\text{new}} = k_{\\text{cat}} [E]_{\\text{total, new}}$$\nSubstituting the expression for $[E]_{\\text{total, new}}$:\n$$V_{\\max, \\text{new}} = k_{\\text{cat}} (0.5 [E]_{\\text{total},0}) = 0.5 (k_{\\text{cat}} [E]_{\\text{total},0})$$\nRecognizing that $V_{\\max,0} = k_{\\text{cat}} [E]_{\\text{total},0}$, we find the relationship between the new and reference maximal velocities:\n$$V_{\\max, \\text{new}} = 0.5 V_{\\max,0}$$\nThis shows that a $50\\%$ reduction in the total concentration of functional enzyme leads to a $50\\%$ reduction in the maximal velocity, as expected.\n\nThe reaction velocity for the patient with the variant, $v_{\\text{new}}$, is given by the Michaelis-Menten equation using the new parameters:\n$$v_{\\text{new}} = \\frac{V_{\\max, \\text{new}} [S]}{K_m + [S]}$$\nSubstituting $V_{\\max, \\text{new}} = 0.5 V_{\\max,0}$:\n$$v_{\\text{new}} = \\frac{0.5 V_{\\max,0} [S]}{K_m + [S]}$$\n\nThe problem asks for the fold-change in reaction velocity, which is the ratio of the new velocity to the reference velocity, $\\frac{v_{\\text{new}}}{v_0}$. We can now compute this ratio for any given substrate concentration $[S]$:\n$$\\frac{v_{\\text{new}}}{v_0} = \\frac{\\frac{0.5 V_{\\max,0} [S]}{K_m + [S]}}{\\frac{V_{\\max,0} [S]}{K_m + [S]}}$$\nThe term $\\frac{V_{\\max,0} [S]}{K_m + [S]}$ is a common factor in both the numerator and the denominator. Provided that $[S] \\neq 0$ (a necessary condition for a reaction to occur), this term is non-zero and can be cancelled.\n$$\\frac{v_{\\text{new}}}{v_0} = 0.5$$\nThe result is a dimensionless constant, $0.5$. This indicates that a $50\\%$ reduction in the total concentration of functional TPMT enzyme results in a $50\\%$ reduction in the reaction velocity at every substrate concentration, not just at saturation. The fold-change is constant across the entire range of $[S]$.", "answer": "$$\\boxed{0.5}$$", "id": "4572500"}, {"introduction": "The bridge from pharmacogenomic theory to clinical practice is built on accurate phenotyping, but this process is fraught with real-world complexities. This exercise challenges you to navigate the preanalytical phase of laboratory testing, where factors like sample handling and patient history can significantly alter measured enzyme activity. By modeling the combined effects of recent blood transfusions, sample storage conditions, and choice of anticoagulant, you will learn to critically evaluate laboratory data and anticipate potential sources of clinical misclassification [@problem_id:4572490].", "problem": "A clinical pharmacology laboratory measures Thiopurine Methyltransferase (TPMT) activity in Red Blood Cell (RBC) hemolysates to phenotype patients prior to thiopurine therapy. The analyte is reported as $\\mathrm{pmol\\;6\\text{-}methylmercaptopurine\\;produced\\;per\\;hour\\;per\\;mg\\;hemoglobin}$, abbreviated here as $\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$. Consider a patient whose true RBC TPMT activity (reflecting intrinsic phenotype in the absence of preanalytical perturbations) is $A_P = 12\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$ (intermediate activity). Normal donor RBCs have TPMT activity $A_D = 24\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$. The laboratory classifies samples as “normal phenotype” if the measured activity satisfies $A_{\\mathrm{meas}} \\ge T$ with $T = 20\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$.\n\nPreanalytical effects to consider:\n\n- Time and temperature: irreversible loss of measurable enzyme activity in stored whole blood follows first-order kinetics where the instantaneous rate of loss is proportional to current activity with temperature-dependent rate constant $k$. For storage at $4^{\\circ}\\mathrm{C}$, use $k_{4} = 0.004\\;\\mathrm{h^{-1}}$. For storage at $22^{\\circ}\\mathrm{C}$, use $k_{22} = 0.020\\;\\mathrm{h^{-1}}$.\n- Anticoagulant: Ethylenediaminetetraacetic acid (EDTA) and heparin are considered neutral for this assay ($f_{\\mathrm{EDTA}} = 1.00$, $f_{\\mathrm{heparin}} = 1.00$). Acid–citrate–dextrose (ACD) mildly lowers apparent activity by $5\\%$ ($f_{\\mathrm{citrate}} = 0.95$) due to pH and ionic effects on catalytic efficiency under the laboratory’s buffer conditions.\n- Recent transfusion: when a patient has recently received a packed RBC transfusion, the measured activity reflects the hemoglobin-weighted mixture of donor and recipient RBCs present at sampling. Let $p$ denote the fraction of donor RBC contribution to the sample’s hemoglobin at the time of draw (assume RBCs from donor and recipient are otherwise equivalent apart from TPMT activity).\n\nAssume the blood sample is drawn, stored unprocessed under the stated conditions for the stated duration, then assayed without any restorative interventions. For each option below, compute the expected measured activity and determine whether the patient would be misclassified as “normal phenotype” based solely on preanalytical variables. Choose all options that would most likely yield $A_{\\mathrm{meas}} \\ge T$ and thus misclassify the patient as normal.\n\n- A: Anticoagulant $=$ EDTA; storage $=$ $48\\;\\mathrm{h}$ at $22^{\\circ}\\mathrm{C}$; recent transfusion with donor fraction $p = 0.50$.\n\n- B: Anticoagulant $=$ heparin; storage $=$ $12\\;\\mathrm{h}$ at $4^{\\circ}\\mathrm{C}$; recent transfusion with donor fraction $p = 0.60$.\n\n- C: Anticoagulant $=$ heparin; storage $=$ $4\\;\\mathrm{h}$ at $4^{\\circ}\\mathrm{C}$; recent transfusion with donor fraction $p = 0.70$.\n\n- D: Anticoagulant $=$ ACD (citrate); storage $=$ $8\\;\\mathrm{h}$ at $4^{\\circ}\\mathrm{C}$; recent transfusion with donor fraction $p = 0.80$.\n\n- E: Anticoagulant $=$ EDTA; storage $=$ $2\\;\\mathrm{h}$ at $22^{\\circ}\\mathrm{C}$; recent transfusion with donor fraction $p = 0.80$.\n\nBase your reasoning only on: first-order kinetics of enzyme activity loss under storage, mixture proportionality of RBC contributions to activity per $\\mathrm{mg}$ hemoglobin, and the stated anticoagulant effect factors.", "solution": "The problem statement is first validated for scientific soundness, self-consistency, and clarity before a solution is attempted.\n\n### Step 1: Extract Givens\nThe explicit data and definitions provided in the problem statement are:\n-   Patient's true RBC TPMT activity: $A_P = 12\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$\n-   Normal donor RBC TPMT activity: $A_D = 24\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$\n-   Threshold for \"normal phenotype\" classification: $A_{\\mathrm{meas}} \\ge T$, where $T = 20\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$\n-   Storage at $4^{\\circ}\\mathrm{C}$: first-order activity loss with rate constant $k_{4} = 0.004\\;\\mathrm{h^{-1}}$\n-   Storage at $22^{\\circ}\\mathrm{C}$: first-order activity loss with rate constant $k_{22} = 0.020\\;\\mathrm{h^{-1}}$\n-   Anticoagulant effect factors:\n    -   EDTA: $f_{\\mathrm{EDTA}} = 1.00$\n    -   Heparin: $f_{\\mathrm{heparin}} = 1.00$\n    -   ACD (citrate): $f_{\\mathrm{citrate}} = 0.95$\n-   Transfusion effect: The measured activity is a hemoglobin-weighted mixture, where $p$ is the fraction of donor RBC contribution to hemoglobin.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the following criteria:\n-   **Scientifically Grounded**: The problem is grounded in established principles of clinical chemistry, pharmacology, and enzyme kinetics. First-order decay is a standard model for protein degradation. The concept of mixed populations of cells (from transfusion) affecting a bulk measurement is valid. The influence of anticoagulants and collection tube additives on assay results is a common preanalytical consideration. The values for TPMT activity are consistent with known phenotypes (homozygous normal, heterozygous/intermediate).\n-   **Well-Posed**: The problem is well-posed. It provides a clear set of initial conditions, a mathematical model for each preanalytical variable, and a specific quantitative question. The combination of these effects into a single predictive model is straightforward, leading to a unique answer for each option.\n-   **Objective**: The problem is stated in objective, technical language. All parameters are quantified, and the relationships are defined mathematically. There is no ambiguity or subjective content.\n-   **Completeness and Consistency**: The problem is self-contained. It provides all necessary data ($A_P, A_D, T, k$ values, $f$ factors) and specifies the conditions for each option. The models for transfusion, storage loss, and anticoagulant effects are independent and can be combined without contradiction.\n-   **Realism**: The scenarios described (storage times, temperatures, transfusion levels, anticoagulant types) are realistic in a clinical setting.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. It is a well-structured, scientifically sound problem in quantitative clinical pharmacology. The solution can now be derived.\n\n### Derivation of the General Model\nThe final measured TPMT activity, $A_{\\mathrm{meas}}$, is a function of three independent preanalytical effects applied to the initial state. The order of operations is as follows:\n1.  **Transfusion**: A blood sample is drawn, which contains a mixture of patient and donor red blood cells (RBCs). The initial TPMT activity of the sample, $A_0$, is the hemoglobin-weighted average of the patient's activity ($A_P$) and the donor's activity ($A_D$). Let $p$ be the fraction of donor RBCs.\n    $$A_0 = (1 - p)A_P + pA_D$$\n2.  **Storage**: The sample is stored for a time $t$ at a temperature with a corresponding rate constant $k$. The activity decays according to first-order kinetics. The activity after storage, $A(t)$, is:\n    $$A(t) = A_0 e^{-kt}$$\n3.  **Anticoagulant**: The assay is performed, and the anticoagulant in the collection tube modifies the apparent activity by a multiplicative factor, $f$. The final measured activity is:\n    $$A_{\\mathrm{meas}} = f \\cdot A(t)$$\n\nCombining these steps yields the general formula for the measured activity:\n$$A_{\\mathrm{meas}} = f \\cdot \\left[ (1 - p)A_P + pA_D \\right] \\cdot e^{-kt}$$\n\nUsing the given constants $A_P = 12\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$ and $A_D = 24\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$, the equation becomes:\n$$A_{\\mathrm{meas}} = f \\cdot \\left[ (1 - p) \\cdot 12 + p \\cdot 24 \\right] \\cdot e^{-kt}$$\n$$A_{\\mathrm{meas}} = f \\cdot \\left[ 12 - 12p + 24p \\right] \\cdot e^{-kt}$$\n$$A_{\\mathrm{meas}} = f \\cdot (12 + 12p) \\cdot e^{-kt}$$\n\nThe patient is misclassified as \"normal phenotype\" if $A_{\\mathrm{meas}} \\ge T$, where $T = 20\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$. We will now evaluate each option using this model.\n\n### Option-by-Option Analysis\n\n**Option A:**\n-   Parameters: $f = f_{\\mathrm{EDTA}} = 1.00$, $t = 48\\;\\mathrm{h}$, $k = k_{22} = 0.020\\;\\mathrm{h^{-1}}$, $p = 0.50$.\n-   Calculation:\n    $$A_0 = 12 + 12(0.50) = 12 + 6 = 18.0\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n    $$kt = (0.020\\;\\mathrm{h^{-1}})(48\\;\\mathrm{h}) = 0.96$$\n    $$A_{\\mathrm{meas}} = 1.00 \\cdot (18.0) \\cdot e^{-0.96} \\approx 18.0 \\cdot 0.38289 \\approx 6.89\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n-   Comparison: $6.89 < 20$. The patient would not be misclassified.\n-   Verdict: **Incorrect**.\n\n**Option B:**\n-   Parameters: $f = f_{\\mathrm{heparin}} = 1.00$, $t = 12\\;\\mathrm{h}$, $k = k_4 = 0.004\\;\\mathrm{h^{-1}}$, $p = 0.60$.\n-   Calculation:\n    $$A_0 = 12 + 12(0.60) = 12 + 7.2 = 19.2\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n    $$kt = (0.004\\;\\mathrm{h^{-1}})(12\\;\\mathrm{h}) = 0.048$$\n    $$A_{\\mathrm{meas}} = 1.00 \\cdot (19.2) \\cdot e^{-0.048} \\approx 19.2 \\cdot 0.95314 \\approx 18.30\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n-   Comparison: $18.30 < 20$. The patient would not be misclassified.\n-   Verdict: **Incorrect**.\n\n**Option C:**\n-   Parameters: $f = f_{\\mathrm{heparin}} = 1.00$, $t = 4\\;\\mathrm{h}$, $k = k_4 = 0.004\\;\\mathrm{h^{-1}}$, $p = 0.70$.\n-   Calculation:\n    $$A_0 = 12 + 12(0.70) = 12 + 8.4 = 20.4\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n    $$kt = (0.004\\;\\mathrm{h^{-1}})(4\\;\\mathrm{h}) = 0.016$$\n    $$A_{\\mathrm{meas}} = 1.00 \\cdot (20.4) \\cdot e^{-0.016} \\approx 20.4 \\cdot 0.98414 \\approx 20.076\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n-   Comparison: $20.076 \\ge 20$. The patient would be misclassified as \"normal phenotype\".\n-   Verdict: **Correct**.\n\n**Option D:**\n-   Parameters: $f = f_{\\mathrm{citrate}} = 0.95$, $t = 8\\;\\mathrm{h}$, $k = k_4 = 0.004\\;\\mathrm{h^{-1}}$, $p = 0.80$.\n-   Calculation:\n    $$A_0 = 12 + 12(0.80) = 12 + 9.6 = 21.6\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n    $$kt = (0.004\\;\\mathrm{h^{-1}})(8\\;\\mathrm{h}) = 0.032$$\n    $$A_{\\mathrm{meas}} = 0.95 \\cdot (21.6) \\cdot e^{-0.032} \\approx 0.95 \\cdot (21.6) \\cdot 0.96850 \\approx 0.95 \\cdot 20.9196 \\approx 19.87\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n-   Comparison: $19.87 < 20$. The patient would not be misclassified. The large transfusion fraction is offset by the citrate anticoagulant effect.\n-   Verdict: **Incorrect**.\n\n**Option E:**\n-   Parameters: $f = f_{\\mathrm{EDTA}} = 1.00$, $t = 2\\;\\mathrm{h}$, $k = k_{22} = 0.020\\;\\mathrm{h^{-1}}$, $p = 0.80$.\n-   Calculation:\n    $$A_0 = 12 + 12(0.80) = 12 + 9.6 = 21.6\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n    $$kt = (0.020\\;\\mathrm{h^{-1}})(2\\;\\mathrm{h}) = 0.04$$\n    $$A_{\\mathrm{meas}} = 1.00 \\cdot (21.6) \\cdot e^{-0.04} \\approx 21.6 \\cdot 0.96079 \\approx 20.75\\;\\mathrm{pmol\\;h^{-1}\\;mg^{-1}}$$\n-   Comparison: $20.75 \\ge 20$. The patient would be misclassified as \"normal phenotype\".\n-   Verdict: **Correct**.", "answer": "$$\\boxed{CE}$$", "id": "4572490"}]}